● Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

Condition: Non-squamous Non-small Cell Lung Cancer · Sponsor: AstraZeneca

PhasePhase 3

Planned participants1160

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with locally advanced or metastatic non-squamous NSCLC whose tumors express PD-L1.

This description comes directly from the study's public registry record.

Talk to the study team

AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com

Always discuss trial participation with your own doctor first.

Locations (287)

Research Site	Mobile, Alabama, United States	Recruiting
Research Site	Chandler, Arizona, United States	Withdrawn
Research Site	Phoenix, Arizona, United States	Recruiting
Research Site	Anaheim, California, United States	Recruiting
Research Site	Beverly Hills, California, United States	Recruiting
Research Site	Loma Linda, California, United States	Not Yet Recruiting
Research Site	Redlands, California, United States	Recruiting
Research Site	San Diego, California, United States	Recruiting
Research Site	San Francisco, California, United States	Recruiting
Research Site	Santa Rosa, California, United States	Recruiting
Research Site	Walnut Creek, California, United States	Recruiting
Research Site	Lone Tree, Colorado, United States	Recruiting

+ 275 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06627647